Pharma Foucs America
lonza-entropic-biosciences-logo
lonza-scalable-3d-human-skin-organoid-model-for-skin-barrier-function-and-injury-screening-webinar-banner lonza-scalable-3d-human-skin-organoid-model-for-skin-barrier-function-and-injury-screening-webinar-sm-banner

Advancing Skin Research: A Scalable 3D Human Skin Organoid Model for Skin Barrier Function and Injury Screening

Human skin models are essential for studying barrier biology, dermatoxicology, and responses to environmental stressors, but many existing in vitro systems require trade-offs between physiological relevance, workflow complexity, and scalability. This webinar will highlight a 96-well compatible, primary cell-based 3D human skin organic platform designed to support more practical and screening-oriented skin research.

In collaboration with Entropic, during this webinar we will introduce a self-organizing 3D skin organoid model generated by co-seeding adult normal human epidermal keratinocytes and adult normal human dermal fibroblasts directly into the ZYRALIX™ platform coated plates using a mixed-medium workflow. The resulting organoids assemble into compact structures, developing bilayer epidermal-dermal organization within days, and continue to mature over a 21-day culture period.

2nd September, 2026     11:00 AM EST

What You Will Learn

  • Understand the process of rapidly generating human 3D skin organoids using ZRYALIX technology.
  • Learn how to functionally characterize advanced skin models, focusing on barrier formation and structural maturation.
  • Explore methods for assessing UV and chemical injury responses in physiologically relevant 3D human skin organoids.

Who Should Attend

  • Lab Scientist
  • Principal Scientist
  • Lab Manager
  • Process Development Scientist
  • R&D

Speakers:

Koh-Meng-Aw-Yong-speaker

Koh Meng Aw Yong
Senior Market Development Manager, Lonza

Koh Meng Aw Yong, PhD, is Senior Market Development Manager at Lonza, where he focuses on the primary cells portfolio, including PBMCs, CD34+ hematopoietic stem cells, hepatocytes, skin, airway, and other cell systems that support drug discovery and translational research. With a background spanning oncology, immunology, cell and gene therapy, and preclinical research solutions, he brings experience across product management, strategic marketing, and scientific innovation. Koh Meng is passionate about helping researchers adopt more predictive biological models and enabling better decision-making across the discovery pipeline.

amir-nasajpour-speaker

Amir Nasajpour
Founder and CEO, Entropic Biosciences

Amir Nasajpour is the Founder and CEO of Entropic Biosciences, a UCLA spinout advancing next-generation new approach methodologies (NAMs) for preclinical testing. Amir earned his PhD in Chemistry and Biochemistry from UCLA in Prof. Weiss's lab, with a focus on materials chemistry, where he pioneered the biomaterials research that became the foundation of ZYRALIX™. His work has been recognized nationally, including as the 2023 National Inventors Hall of Fame Collegiate Inventors Competition Graduate Runner-Up.